Scheuren’s passion for the Bio-Health industry began in 2005, when he launched Axoglia Therapeutics SA as an adviser, later becoming the CEO in 2006. The company is active in the development of innovative molecules in the neurodegenerative diseases field for diseases such as Alzheimer’s, Multiple Sclerosis, and Parkinson’s disease.

Scheuren worked with the Ministry of Economy and SNCI (Société Nationale de Crédit et d’Investissement) in the development of support programs for biotech companies in Luxembourg.

In 2009, he accepted the position of President in Luxembourg’s Biohealth Cluster to develop the life science sector as one of the pillars of economy locally. He has been witness to the impressive development of public research infrastructures and skills, followed today by a private sector, rendering Luxembourg a fertile host country for continuing life science endeavors.

Since 2012, he has been the founder and co-investor of the House of Bio-Health Project, which is hub playing host to innovative companies in Biotechnology, Clean-tech, and ICT-Health IT. The first phase of the project, which included 3,200m2 of laboratory space and 2,000m2 of offices, conferences, and meeting rooms, was inaugurated in mid-2014. Phase II of the House of Bio-Health Project, doubling the surface area of project, was inaugurated in 2017.

As an entrepreneur, he invests and assists regularly in the development and financing of life science start-ups. One of Scheuren’s last investments was in Doctena, a Health IT platform dedicated to booking appointments for health care professionals.

In 1991 he became a founder of the first private pharmaceutical manufacturing company in Georgia.

In 1995 he relocated to Russian Federation and founded several pharmaceutical companies including Arbacom, Ltd. – one of the leading distributors and manufacturers of pharmaceutical products, and Valexpharm Ltd – an R&D company geared towards development and introduction to the market of original drugs. In 2006 these companies were sold to financial institutions.

Later on (2005-2009) he was invited to run a consolidated pharmaceutical business for one of the largest Russian financial conglomerate, listed on London Stock Exchange Russian public company FSC “Systema”. He was member of the executive board of FSC “Systema” and CEO of ZAO “Binnopharm”. Being CEO of ZAO “Binnopharm” he was involved with personnel management, construction and setting up of pharmaceutical facilities, pharmaceutical manufacturing and sales of pharmaceutical products.

At the present time Alexander Bakhutashvili has concentrate his efforts on development of innovative drugs and drug repositioning as a President of Valexpharm Ltd., Member of Board and Chief Scientific Officer of Marco Polo Pharmaceuticals, a Luxembourg based drug-repositioning company.

His business expertise field is Russian and Georgian pharmaceutical market economy, market access and drug development.

After leaving BDA, he founded Prescriptia – a consulting company specializing in drug regulation and pharmacoeconomics headquartered in Sofia, Bulgaria. Dr. Borissov is a lecturer at the Faculty of Public Health at Medical University of Sofia. He also provides lectures and training programs in Europe, Asia and Africa. He has authored and co-authored over 50 highly cited research papers, books and monographs.

Elena began her professional career as a neurologist in the Chelyabinsk Regional Clinical Hospital. Between 1994 and 2001, she worked as the chief economist of the credit department at the Promstroybank of Russia. And then, she worked for the Ministry of Health. In 2004, she moved to private sector. From 2008 to 2016, she was working for BioMed company; first as the general director of research and then as CFO. In 2016, she has joined Pharmaccess LLC where she is working as CFO.

After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993.In 1995 he embraces a carrier in the pharmaceutical industry for 13 years.Mondher Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence.

In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making.

In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD) an international course already followed by about 500 students. Additionally, he recently created the Market Access Society to promote research and scientific activities around market access, public health and health economic assessment. Since 2009, he also chairs the Annual Market Access Day, a purely academic event. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP).

Since September 2014, he joined the research unit EA3279 of the public health department, at Aix-Marseille University (France) as full Professor. Mondher Toumi is also visiting Professor at Beijing University (Third Hospital).

He is a recognized expert in health economics and an authority on market access and risk management. He has more than 200 scientific publications and oral communications, and has contributed to several books. He authored a reference book on Market Access.